Clinical
setting
Aims Name of the trial PI
Heart
Failure  
In line with landmark pioneering, multicenter RCTs with mineralocorticoid receptor antagonists (MRA) in heart failure RALES, EPHESUS, EMPHASIS-HF) EU FP7 Homage F. Zannad
Proof of concept RCT in 1000 HF prone patients (spiro vs. placebo), stratified on a BM footprint RALES, EPHESUS,
EMPHASIS-HF)
F. Zannad
Validate a patient-centered remote-monitoring loop in HF / patients (point of care device for the daily selfmeasurement of relevant cardiorenal biomarkers in a single fingertip drop of blood) CARE-MOST HF P. Rossignol
Hyper
tension 
Step-down of anti-hypertensive treatment in very old frail patients RCT-H2020 application
(second stage)
A. Benetos (coord.) and P.
Rossignol
Barostimulation in resistant hypertension PROBE design 160 patients multicenter RCT PRME-BAROSTIM Coord. P. Rossignol
Other  Hemodialysis patients RCT MRA : spironolactone vs. placebo (850 patients, >60 centers) RCT PHRCALCHEMIST P. Rossignol and
L. Frimat
Innovative therapy for modulating excessive inflammation, based on antagonist of TREM receptors, and targeting acute ischemic CV diseases and septic shock: Phase I Inno-TREM S. Gibot and the
SME InnoTREM

 

 

 

FHU-CARTAGE © 2015 - BY MLCOM

Legal notices | Contact

We use cookies to improve our website. Cookies used for the essential operation of this site have already been set. For more information visit our Cookie policy. I accept cookies from this site.Agree